Homevideos Newsbusiness News

    Big Deal: Biocon Biologics to buy Viatris biosimilars biz; says deal will turn firm into a biosimilar growth engine

    videos | IST

    Big Deal: Biocon Biologics to buy Viatris biosimilars biz; says deal will turn firm into a biosimilar growth engine

    Mini

    Biocon subsidiary Biocon Biologics' has entered into a definitive agreement with Viatris to acquire the US-based company's biosimilars business. Speaking exclusively to CNBC-TV18, Kiran Mazumdar Shaw, Executive Chairperson of Biocon said the deal will boost Biocon Biologics into a global biosimilar growth engine.

    Biocon subsidiary Biocon Biologics' has entered into a definitive agreement with Viatris to acquire the US-based company's biosimilars business.
    The deal is worth up to $3.335 billion in stock and cash, said the Biocon arm, which aims to create a unique fully integrated global biosimilars enterprise.
    Speaking exclusively to CNBC-TV18, Kiran Mazumdar Shaw, Executive Chairperson of Biocon said the deal will boost Biocon Biologics into a global biosimilar growth engine.
    "This is a huge inflection point for us as a company and our biosimilar's business. We always wanted to bolt on a front facing commercial engine for our biosimilars business and this accelerates that process and that is why this transaction makes a lot of sense."
    "It has been our aspiration to be a global world beating biosimilars company. This transaction catapults us into global big league. Viatris has been our partners for over a decade and this deal enables us to seamlessly move from our current partnership model into a wholly integrated standalone biosimilars biologics enterprise."
    Watch video for entire discussion.
    next story

      Market Movers

      View All
      CompanyPriceChng%Chng